Statins in Non-alcoholic Steatohepatitis

Non-alcoholic fatty liver disease (NAFLD) is the primary cause of chronic liver disease. The range is extensive, including hepatocellular carcinoma, cirrhosis, fibrosis, fatty liver, and non-alcoholic steatohepatitis (NASH). NASH is a condition related to obesity, overweight, metabolic syndrome, dia...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jose D. Torres-Peña, Laura Martín-Piedra, Francisco Fuentes-Jiménez
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	statins NASH cardiovascular disease liver aminotransferase Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/d2e4d270a49241b4bc559e2a4a558e61
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d2e4d270a49241b4bc559e2a4a558e61
record_format	dspace
spelling	oai:doaj.org-article:d2e4d270a49241b4bc559e2a4a558e612021-11-30T18:12:21ZStatins in Non-alcoholic Steatohepatitis2297-055X10.3389/fcvm.2021.777131https://doaj.org/article/d2e4d270a49241b4bc559e2a4a558e612021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fcvm.2021.777131/fullhttps://doaj.org/toc/2297-055XNon-alcoholic fatty liver disease (NAFLD) is the primary cause of chronic liver disease. The range is extensive, including hepatocellular carcinoma, cirrhosis, fibrosis, fatty liver, and non-alcoholic steatohepatitis (NASH). NASH is a condition related to obesity, overweight, metabolic syndrome, diabetes, and dyslipidemia. It is a dynamic condition that can regress to isolated steatosis or progress to fibrosis and cirrhosis. Statins exert anti-inflammatory, proapoptotic, and antifibrotic effects. It has been proposed that these drugs could have a relevant role in NASH. In this review, we provide an overview of current evidence, from mechanisms of statins involved in the modulation of NASH to human trials about the use of statins to treat or attenuate NASH.Jose D. Torres-PeñaJose D. Torres-PeñaLaura Martín-PiedraLaura Martín-PiedraFrancisco Fuentes-JiménezFrancisco Fuentes-JiménezFrontiers Media S.A.articlestatinsNASHcardiovascular diseaseliveraminotransferaseDiseases of the circulatory (Cardiovascular) systemRC666-701ENFrontiers in Cardiovascular Medicine, Vol 8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	statins NASH cardiovascular disease liver aminotransferase Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	statins NASH cardiovascular disease liver aminotransferase Diseases of the circulatory (Cardiovascular) system RC666-701 Jose D. Torres-Peña Jose D. Torres-Peña Laura Martín-Piedra Laura Martín-Piedra Francisco Fuentes-Jiménez Francisco Fuentes-Jiménez Statins in Non-alcoholic Steatohepatitis
description	Non-alcoholic fatty liver disease (NAFLD) is the primary cause of chronic liver disease. The range is extensive, including hepatocellular carcinoma, cirrhosis, fibrosis, fatty liver, and non-alcoholic steatohepatitis (NASH). NASH is a condition related to obesity, overweight, metabolic syndrome, diabetes, and dyslipidemia. It is a dynamic condition that can regress to isolated steatosis or progress to fibrosis and cirrhosis. Statins exert anti-inflammatory, proapoptotic, and antifibrotic effects. It has been proposed that these drugs could have a relevant role in NASH. In this review, we provide an overview of current evidence, from mechanisms of statins involved in the modulation of NASH to human trials about the use of statins to treat or attenuate NASH.
format	article
author	Jose D. Torres-Peña Jose D. Torres-Peña Laura Martín-Piedra Laura Martín-Piedra Francisco Fuentes-Jiménez Francisco Fuentes-Jiménez
author_facet	Jose D. Torres-Peña Jose D. Torres-Peña Laura Martín-Piedra Laura Martín-Piedra Francisco Fuentes-Jiménez Francisco Fuentes-Jiménez
author_sort	Jose D. Torres-Peña
title	Statins in Non-alcoholic Steatohepatitis
title_short	Statins in Non-alcoholic Steatohepatitis
title_full	Statins in Non-alcoholic Steatohepatitis
title_fullStr	Statins in Non-alcoholic Steatohepatitis
title_full_unstemmed	Statins in Non-alcoholic Steatohepatitis
title_sort	statins in non-alcoholic steatohepatitis
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/d2e4d270a49241b4bc559e2a4a558e61
work_keys_str_mv	AT josedtorrespena statinsinnonalcoholicsteatohepatitis AT josedtorrespena statinsinnonalcoholicsteatohepatitis AT lauramartinpiedra statinsinnonalcoholicsteatohepatitis AT lauramartinpiedra statinsinnonalcoholicsteatohepatitis AT franciscofuentesjimenez statinsinnonalcoholicsteatohepatitis AT franciscofuentesjimenez statinsinnonalcoholicsteatohepatitis
_version_	1718406412013404160

Statins in Non-alcoholic Steatohepatitis

Ejemplares similares